Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Winnergy Medical Public Company Limited (WINMED.BK)
Bangkok, TH
Winnergy Medical Public Company Limited, headquartered in Bangkok, Thailand, operates as a distributor of diverse medical and diagnostic equipment throughout the nation. Founded in 2004, the company offers a broad portfolio of healthcare solutions. These include women's health products such as prenatal genetic and Down's syndrome screening tests, pregnancy monitoring devices, and cervical dilators. Winnergy Medical also provides tools for assessing blood quality for transfusions, kits for detecting blood infections, and systems for stem cell and contamination analysis. Furthermore, it distributes mosquito traps for both indoor and outdoor use and offers COVID-19 diagnostic laboratory services. The company adopted its current name, Winnergy Medical Public Company Limited, in September 2020, having previously been known as Winnergy Medical Co., Ltd.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -1.14% | -1.14% | -13.00% | -14.71% | -12.12% | -26.89% | -76.36% | -84.46% | -71.94% | -71.94% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Medical - Distribution: +5.6%-1.1% Q1'26: -3.6% (vs Q1'25)
-
EPS growth Medical - Distribution: +4.9%-48.2% Q1'26: -47.4% (vs Q1'25)
-
FCF margin FCF growth · Medical - Distribution: +37.6%-14.0% Q1'26: -22.5% (vs Q1'25)
-
EBIT margin Medical - Distribution: +3.0%+1.3% Q1'26: -3.3% (vs Q1'25)
-
ROIC Medical - Distribution: +5.7%+0.7% Q1'26: -1.5% (vs Q1'25)
-
Share dilution Medical - Distribution: +0.0%+0.0% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Distribution: 0.87×5.95× Q1'26: 13.44× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 5/5 |
| 2026-05-28 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 5/5 |
| 2026-05-27 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 5/5 |
| 2026-05-26 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 5/5 |
| 2026-05-25 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 5/5 |
| 2026-05-22 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-21 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-20 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-19 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-18 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-15 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-14 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-13 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-12 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-11 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-08 | B- | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 2/5 | 5/5 |
| 2026-05-07 | B- | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 2/5 | 5/5 |
| 2026-05-06 | B- | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 2/5 | 5/5 |
| 2026-05-05 | B- | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 2/5 | 5/5 |
| 2026-04-30 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 5/5 |
| 2026-04-29 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 5/5 |
| 2026-04-28 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 5/5 |
| 2026-04-27 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 5/5 |
| 2026-04-24 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 5/5 |
| 2026-04-23 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 5/5 |
| 2026-04-22 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 5/5 |
| 2026-04-21 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 5/5 |
| 2026-04-20 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 5/5 |
| 2026-04-17 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 5/5 |
| 2026-04-16 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ampaporn Lamlertsaringkarn | Chief Financial Officer | — | female |
| Chawanpat Homhwantip | Head of Internal Audit | — | female |
| Kamol Sakulworapatsiri | Vice President of Finance Department | — | male |
| Mathurada Muanjumpon | Head of Accounting | — | female |
| Nanthiya Darakananda | Chief Executive Officer & Director | — | male |
| Olarn Jarungthamchote | Head of the Compliance Unit | — | male |
| Pavarisa Damrongsuntisuk | Company Secretary | — | female |
| Rachan Arayawongchai | Chief Financial Officer | — | male |
| Thidapat Promsuwan | Vice President of Accounting | — | female |
| Wanwisa Soisawat | Company Secretary & Head of Investor Relations | — | female |
| Yodjuta kunjara Na Ayudhya | Chief Operating Officer | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for WINMED.BK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
